CeQur builds wearable insulin delivery patches for diabetes patients to simplify daily injections.
$100MSeries E
Investor undisclosed
A $100M Series E for a wearable insulin patch signals that large-scale reimbursement and clinical validation are now table stakes—this isn't about proving efficacy anymore, it's about manufacturing scale and market penetration. If you're building hardware in regulated health, watch how CeQur deploys this capital between supply chain, geographic expansion, and payer relationships; that ratio tells you what the actual bottleneck is right now.